Identification

Name
Pipotiazine
Accession Number
DB01621
Type
Small Molecule
Groups
Approved, Investigational
Description

Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.

Structure
Thumb
Synonyms
  • Piportil
  • Pipothiazine
  • Pipotiazina
  • Pipotiazinum
Product Ingredients
IngredientUNIICASInChI Key
Pipotiazine palmitate4Q3H01QRMI37517-26-3KTOYYUONFQWSMW-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Piportil L4Solution25 mgIntramuscularSanofi Aventis1980-12-312016-08-17Canada
Piportil L4Solution50 mgIntramuscularSanofi Aventis1980-12-312017-03-30Canada
Categories
UNII
L903J9JPYV
CAS number
39860-99-6
Weight
Average: 475.667
Monoisotopic: 475.196333317
Chemical Formula
C24H33N3O3S2
InChI Key
JOMHSQGEWSNUKU-UHFFFAOYSA-N
InChI
InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3
IUPAC Name
10-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl}-N,N-dimethyl-10H-phenothiazine-2-sulfonamide
SMILES
CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1

Pharmacology

Indication

For the maintenance treatment of chronic non-agitated schizophrenic patients.

Structured Indications
Pharmacodynamics

Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It reduces activity of dopamine receptors in the limbic system. Its 5-HT antagonism helps normalize dopamine activity in the cortical regions.

Mechanism of action

Pipotiazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 1A
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Pipotiazine.Investigational
2,5-Dimethoxy-4-ethylamphetaminePipotiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetaminePipotiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetaminePipotiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePipotiazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pipotiazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Pipotiazine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Pipotiazine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pipotiazine.Approved, Investigational, Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Pipotiazine.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pipotiazine.Approved, Illicit
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Pipotiazine.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pipotiazine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pipotiazine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipotiazine.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Pipotiazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulpridePipotiazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pipotiazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipotiazine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pipotiazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Amperozide.Experimental
AmphetaminePipotiazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
ApalutamideThe serum concentration of Pipotiazine can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Pipotiazine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipotiazine.Approved, Investigational
ArmodafinilThe metabolism of Pipotiazine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Pipotiazine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pipotiazine.Approved
AtazanavirThe metabolism of Pipotiazine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Pipotiazine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Azaperone.Investigational, Vet Approved
AzelastinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Pipotiazine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pipotiazine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Pipotiazine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Barbital.Illicit
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Pipotiazine.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Benzocaine.Approved, Investigational
BenzphetaminePipotiazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Pipotiazine can be decreased when combined with Betaxolol.Approved, Investigational
BoceprevirThe metabolism of Pipotiazine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Pipotiazine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pipotiazine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipotiazine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipotiazine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pipotiazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Pipotiazine.Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Bupivacaine.Approved, Investigational
BuprenorphinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Pipotiazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipotiazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipotiazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pipotiazine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipotiazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pipotiazine.Approved
CaffeineThe metabolism of Pipotiazine can be decreased when combined with Caffeine.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Pipotiazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pipotiazine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Pipotiazine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pipotiazine.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pipotiazine.Experimental
CelecoxibThe metabolism of Pipotiazine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pipotiazine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pipotiazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Pipotiazine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pipotiazine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Pipotiazine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipotiazine.Approved
ChlorphenterminePipotiazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Pipotiazine can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pipotiazine.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pipotiazine.Approved
CholecalciferolThe metabolism of Pipotiazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pipotiazine.Experimental
CimetidineThe metabolism of Pipotiazine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Pipotiazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Pipotiazine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Pipotiazine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pipotiazine can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pipotiazine.Approved
ClobazamThe metabolism of Pipotiazine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Pipotiazine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Pipotiazine can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pipotiazine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pipotiazine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipotiazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Pipotiazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Pipotiazine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Pipotiazine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pipotiazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pipotiazine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Pipotiazine.Approved, Investigational
CrizotinibThe metabolism of Pipotiazine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pipotiazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipotiazine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Pipotiazine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pipotiazine.Approved
Cyproterone acetateThe serum concentration of Pipotiazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pipotiazine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pipotiazine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Pipotiazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Pipotiazine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Pipotiazine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pipotiazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Pipotiazine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Pipotiazine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipotiazine.Approved
DesipramineThe metabolism of Pipotiazine can be decreased when combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipotiazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipotiazine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetaminePipotiazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pipotiazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pipotiazine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Diethyl ether.Experimental
DiethylpropionPipotiazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pipotiazine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipotiazine.Approved, Illicit
DihydroergotamineThe metabolism of Pipotiazine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Pipotiazine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipotiazine.Approved
DiphenhydramineThe metabolism of Pipotiazine can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipotiazine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Pipotiazine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Pipotiazine.Approved, Investigational
DoxycyclineThe metabolism of Pipotiazine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pipotiazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Illicit
DronedaroneThe metabolism of Pipotiazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pipotiazine.Approved, Investigational
DuloxetineThe metabolism of Pipotiazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Pipotiazine can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipotiazine.Approved, Investigational
EliglustatThe metabolism of Pipotiazine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Eltanolone.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pipotiazine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pipotiazine.Approved, Investigational
EnzalutamideThe serum concentration of Pipotiazine can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipotiazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipotiazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pipotiazine.Approved
ErythromycinThe metabolism of Pipotiazine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pipotiazine.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Pipotiazine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Pipotiazine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pipotiazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipotiazine.Approved, Investigational
EthanolPipotiazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipotiazine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pipotiazine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Pipotiazine can be decreased when combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Pipotiazine.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pipotiazine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipotiazine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pipotiazine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pipotiazine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Pipotiazine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Pipotiazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipotiazine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipotiazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipotiazine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pipotiazine.Approved
FluvoxamineThe metabolism of Pipotiazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Pipotiazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pipotiazine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Pipotiazine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Pipotiazine.Approved, Investigational
Fusidic AcidThe serum concentration of Pipotiazine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipotiazine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pipotiazine.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Pipotiazine can be decreased when combined with Gemfibrozil.Approved
GepefrinePipotiazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pipotiazine.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Pipotiazine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Pipotiazine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Pipotiazine.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pipotiazine.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Pipotiazine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pipotiazine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Pipotiazine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Pipotiazine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Hexobarbital.Approved
HydrocodonePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipotiazine.Approved, Illicit
HydroxyamphetaminePipotiazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
IdelalisibThe metabolism of Pipotiazine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Iloperidone.Approved
ImatinibThe metabolism of Pipotiazine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Pipotiazine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Pipotiazine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Indiplon.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Pipotiazine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Pipotiazine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Pipotiazine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Pipotiazine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Pipotiazine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Pipotiazine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pipotiazine.Approved
Iofetamine I-123Pipotiazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsavuconazoleThe serum concentration of Pipotiazine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Pipotiazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipotiazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pipotiazine.Approved, Vet Approved
IsoniazidThe metabolism of Pipotiazine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Pipotiazine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Pipotiazine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pipotiazine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipotiazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Pipotiazine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipotiazine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pipotiazine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pipotiazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pipotiazine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipotiazine.Approved
LidocaineThe metabolism of Pipotiazine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Pipotiazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Pipotiazine.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Pipotiazine.Approved
LisdexamfetaminePipotiazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Pipotiazine.Approved
LobeglitazoneThe metabolism of Pipotiazine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Pipotiazine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pipotiazine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pipotiazine.Approved
LorcaserinThe metabolism of Pipotiazine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Pipotiazine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Pipotiazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipotiazine.Approved
LuliconazoleThe serum concentration of Pipotiazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pipotiazine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Pipotiazine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Pipotiazine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Pipotiazine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipotiazine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pipotiazine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Melperone.Approved, Investigational
MephedronePipotiazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePipotiazine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipotiazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Meptazinol.Experimental
MequitazinePipotiazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipotiazine.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine.Approved
MethadoneThe metabolism of Pipotiazine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetaminePipotiazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipotiazine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipotiazine.Approved
MethotrimeprazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenaminePipotiazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipotiazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pipotiazine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Pipotiazine.Approved
MexiletineThe metabolism of Pipotiazine can be decreased when combined with Mexiletine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipotiazine.Approved, Illicit
MidomafetaminePipotiazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Pipotiazine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Pipotiazine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pipotiazine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Pipotiazine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Pipotiazine.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
MirabegronThe metabolism of Pipotiazine can be decreased when combined with Mirabegron.Approved
MirtazapinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Pipotiazine.Approved, Investigational
MitotaneThe serum concentration of Pipotiazine can be decreased when it is combined with Mitotane.Approved
MMDAPipotiazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Pipotiazine can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Pipotiazine can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pipotiazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipotiazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pipotiazine.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Pipotiazine.Approved, Investigational
NefazodoneThe metabolism of Pipotiazine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Pipotiazine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Pipotiazine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Pipotiazine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Pipotiazine can be decreased when combined with Nicardipine.Approved, Investigational
NilotinibThe metabolism of Pipotiazine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipotiazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pipotiazine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pipotiazine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pipotiazine.Approved, Investigational
OlaparibThe metabolism of Pipotiazine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pipotiazine.Approved
OmeprazoleThe metabolism of Pipotiazine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Opium.Approved, Illicit
OrphenadrinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Pipotiazine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipotiazine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipotiazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipotiazine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Pipotiazine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipotiazine.Approved
PanobinostatThe serum concentration of Pipotiazine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pipotiazine can be decreased when combined with Pantoprazole.Approved
ParaldehydePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Pipotiazine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Pipotiazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipotiazine.Approved, Vet Approved
PentobarbitalThe metabolism of Pipotiazine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipotiazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipotiazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipotiazine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Pipotiazine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Pipotiazine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Phenoxyethanol.Approved
PhenterminePipotiazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Pipotiazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipotiazine.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pipotiazine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pipamperone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Pipotiazine.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Pipotiazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePipotiazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Pipotiazine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Pipotiazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Pipotiazine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pipotiazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipotiazine.Approved, Vet Approved
PromazineThe metabolism of Pipotiazine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pipotiazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pipotiazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipotiazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Pipotiazine is combined with PSD502.Investigational
PseudoephedrinePipotiazine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipotiazine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipotiazine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Pipotiazine.Approved, Investigational
QuinidineThe metabolism of Pipotiazine can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Pipotiazine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pipotiazine.Approved, Investigational
RanolazineThe metabolism of Pipotiazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipotiazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipotiazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Pipotiazine.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipotiazine.Approved, Investigational
RifabutinThe metabolism of Pipotiazine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Pipotiazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pipotiazine can be increased when combined with Rifapentine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pipotiazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ritanserin.Investigational
RitobegronPipotiazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Pipotiazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pipotiazine.Approved
RolapitantThe metabolism of Pipotiazine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Romifidine.Vet Approved
RopinirolePipotiazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pipotiazine.Approved, Investigational
RotigotinePipotiazine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Pipotiazine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pipotiazine.Approved
SaquinavirThe metabolism of Pipotiazine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Pipotiazine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pipotiazine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipotiazine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipotiazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Pipotiazine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Pipotiazine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipotiazine.Approved, Vet Approved
SildenafilThe metabolism of Pipotiazine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pipotiazine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Pipotiazine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pipotiazine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Pipotiazine.Investigational
St. John's WortThe serum concentration of Pipotiazine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Pipotiazine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine.Approved, Investigational
SulfisoxazoleThe metabolism of Pipotiazine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pipotiazine.Approved, Investigational
SulpiridePipotiazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Pipotiazine.Approved, Investigational
SuvorexantPipotiazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pipotiazine.Approved
TelaprevirThe metabolism of Pipotiazine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Pipotiazine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipotiazine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Pipotiazine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Pipotiazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Pipotiazine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipotiazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tetrodotoxin.Investigational
ThalidomidePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Pipotiazine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pipotiazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipotiazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pipotiazine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Pipotiazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tilidine.Experimental
TipranavirThe metabolism of Pipotiazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pipotiazine.Approved, Investigational
TocilizumabThe serum concentration of Pipotiazine can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Pipotiazine.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pipotiazine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pipotiazine.Approved, Withdrawn
TopiramateThe metabolism of Pipotiazine can be decreased when combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipotiazine.Approved, Investigational
TranylcypromineThe metabolism of Pipotiazine can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pipotiazine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipotiazine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipotiazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pipotiazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pipotiazine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Pipotiazine.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Valproic Acid.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pipotiazine.Approved
VenlafaxineThe metabolism of Pipotiazine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Veralipride.Experimental
VerapamilThe metabolism of Pipotiazine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pipotiazine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pipotiazine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pipotiazine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Pipotiazine.Approved, Investigational
VoriconazoleThe metabolism of Pipotiazine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pipotiazine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipotiazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Pipotiazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipotiazine.Approved, Investigational
ZolpidemPipotiazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pipotiazine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pipotiazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Pipotiazine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipotiazine.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food to decrease irritation

References

General References
  1. Bechelli LP, Ruffino-Netto A, Hetem G: A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients. Braz J Med Biol Res. 1983 Dec;16(4):305-11. [PubMed:6143579]
External Links
Human Metabolome Database
HMDB0015558
KEGG Drug
D08385
PubChem Compound
62867
PubChem Substance
46508263
ChemSpider
56598
BindingDB
81798
ChEMBL
CHEMBL398880
PharmGKB
PA10158
Wikipedia
Pipotiazine
ATC Codes
N05AC04 — Pipotiazine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentPsychosis Nos/Other1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntramuscular25 mg
SolutionIntramuscular50 mg
Prices
Unit descriptionCostUnit
Piportil L4 50 mg/ml56.19USD ml
Piportil L4 25 mg/ml17.45USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP3.94ALOGPS
logP3.13ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)17.09ChemAxon
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.09 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity134.12 m3·mol-1ChemAxon
Polarizability53.17 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9896
Blood Brain Barrier+0.9461
Caco-2 permeable-0.6479
P-glycoprotein substrateSubstrate0.7257
P-glycoprotein inhibitor IInhibitor0.774
P-glycoprotein inhibitor IINon-inhibitor0.5492
Renal organic cation transporterNon-inhibitor0.6426
CYP450 2C9 substrateNon-substrate0.6896
CYP450 2D6 substrateNon-substrate0.747
CYP450 3A4 substrateSubstrate0.5077
CYP450 1A2 substrateNon-inhibitor0.8021
CYP450 2C9 inhibitorNon-inhibitor0.8585
CYP450 2D6 inhibitorNon-inhibitor0.764
CYP450 2C19 inhibitorNon-inhibitor0.6829
CYP450 3A4 inhibitorInhibitor0.5623
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6904
Ames testNon AMES toxic0.6482
CarcinogenicityNon-carcinogens0.7615
BiodegradationNot ready biodegradable0.9723
Rat acute toxicity2.5406 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8642
hERG inhibition (predictor II)Inhibitor0.5429
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Piperidines / Organosulfonamides / Benzenoids / 1,4-thiazines / Aminosulfonyl compounds / Trialkylamines / Azacyclic compounds / Primary alcohols
show 3 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Piperidine / Organosulfonic acid amide / Benzenoid / Para-thiazine / Organic sulfonic acid or derivatives
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  3. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263]
  4. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630]
  7. Boireau A, Chambry J, Dubedat P, Farges G, Carruette AM, Zundel JL, Blanchard JC: Enhancing effect of dopamine blockers on evoked acetylcholine release in rat striatal slices: a classical D-2 antagonist response? Eur J Pharmacol. 1986 Aug 22;128(1-2):93-8. [PubMed:2875894]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134]
  2. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. doi: 10.1016/j.bcp.2010.06.045. Epub 2010 Jul 6. [PubMed:20615392]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. [PubMed:19902987]
  2. Bhoopathy S, Xin B, Unger SE, Karnes HT: A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes. J Pharm Biomed Anal. 2005 Apr 1;37(4):739-49. Epub 2004 Dec 30. [PubMed:15797796]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. doi: 10.1016/j.bcp.2010.06.045. Epub 2010 Jul 6. [PubMed:20615392]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. doi: 10.1016/j.bcp.2010.06.045. Epub 2010 Jul 6. [PubMed:20615392]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]

Drug created on August 29, 2007 14:16 / Updated on May 02, 2018 01:25